Gores G J
Division of Gastroenterology and Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Gastroenterol Clin North Am. 1993 Jun;22(2):285-99.
Recent progress has been made in identifying patients with malignant primary liver tumors who have the best chance of long-term survival after orthotopic liver transplantation. Patients with UICC stages I or II hepatocellular carcinoma, the fibrolamellar variant of hepatocellular carcinoma, or epithelioid hepatic hemangioendothelioma are acceptable candidates for orthotopic liver transplantation. Carefully selected patients with neuroendocrine tumors metastatic to the liver may also have long-term palliation with liver transplantation. Therapeutic strategies are currently being developed to minimize disease recurrence after liver transplantation for patients with advanced-stage hepatocellular carcinoma confined to the liver or with cholangiocarcinoma. However, published survival rates for most patients with malignant primary liver tumors remain suboptimal, and significant progress in preventing disease recurrence is required before liver transplantation can be widely applied to most patients with primary malignant liver tumors.
在确定原位肝移植后最有可能长期存活的原发性恶性肝肿瘤患者方面已取得了进展。国际抗癌联盟（UICC）I期或II期肝细胞癌、纤维板层型肝细胞癌或上皮样肝血管内皮瘤患者是原位肝移植的合适候选者。经过精心挑选的肝转移神经内分泌肿瘤患者也可能通过肝移植获得长期缓解。目前正在制定治疗策略，以尽量减少晚期局限于肝脏的肝细胞癌或胆管癌患者肝移植后的疾病复发。然而，大多数原发性恶性肝肿瘤患者公布的生存率仍不理想，在肝移植能够广泛应用于大多数原发性恶性肝肿瘤患者之前，需要在预防疾病复发方面取得重大进展。
